IDRx is a clinical-stage biopharmaceutical company dedicated to developing and commercializing precision therapeutics for the treatment of cancers with well-characterized biology and significant unmet medical need. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong patients’ response to therapy. Founded in 2021, the IDRx team has deep expertise in drug development and have collectively contributed to the discovery, development, and commercialization of more than 10 approved products.
